2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hagen F. Kennecke, MD, MHA, FRCPC, discusses multidisciplinary interactions within Virginia Mason Medical Center for patients with gastroenteropancreatic neuroendocrine tumors.
Hagen F. Kennecke, MD, MHA, FRCPC, a medical oncologist at Virginia Mason Medical Center, discusses multidisciplinary interactions within Virginia Mason Medical Center for patients with gastroenteropancreatic neuroendocrine tumors.
At a weekly tumor board, Kennecke will present a patient’s history, provide their background, and sequentially review pathology. Pathology must be analyzed to ensure the tumor grade is assessed with Ki-67 differentiation. After, imaging is conducted and repeat imaging is ordered if multi-phase CT scans are not completed, says Kennecke.
Then, the Gallium-68 dotatate (Netspot) PET/CT scan is reviewed and a Krenning score is assigned to all patients, grading to tumors from 0 to 4, according to Kennecke. From this evaluation of the patient, the tumor board decides what the best strategy is before discussing with the patients, he concludes.
Related Content: